Looking Ahead: The Future of Chronic GVHD Management and Patient Care

Opinion
Video

Panelists conclude by discussing the future of graft-versus-host disease management, expressing their hopes for the current treatment landscape and potential advancements that could further improve patient outcomes and quality of life.

Video content above is prompted by the following:

Can you tell us about axatilimab and its potential role in cGVHD treatment? How does its mechanism of action differ from other therapies? Please briefly highlight the AGAVE-201 trial and data.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
2 experts are featured in this series.
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Related Content
Photo of a patient holding a prescription bottle of pills and speaking with a doctor holding a clipboard

Pacritinib Shows Preliminary ORR in Chronic Graft-Vs-Host Disease

Kristi Rosa
April 9th 2025
Article

Pacritinib showed early activity and was safe for patients with multi-refractory chronic graft-vs-host disease.

dark blue background with a white outline indicating blood cells

MaaT013 Achieves Primary Endpoint in ARES Trial for GI-aGVHD

Kyle Doherty
January 16th 2025
Article

MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.

diverse hands being raised

How to Overcome 4 Common Barriers to Cancer Clinical Trial Access

Brielle Benyon
November 7th 2024
Article

An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and what clinicians can do to mitigate these disparities.

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

Darlene Dobkowski, MA
August 14th 2024
Article

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Chris Ryan
August 11th 2024
Article

The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.

Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT

Matched and Mismatched Unrelated Donors May Confer Similar Survival Rates for HCT

Roman Fabbricatore
July 30th 2024
Article

Taking mismatched unrelated donors into consideration may increase donor numbers, especially for patients with minority ancestry who are seeking hematopoietic cell transplantation.